Joseph H. Gardner
Fondatore presso Aerpio Therapeutics, Inc.
Posizioni attive di Joseph H. Gardner
Società | Posizione | Inizio | Fine |
---|---|---|---|
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Direttore/Membro del Consiglio | 01/01/2011 | - |
Fondatore | 01/01/2011 | - | |
Presidente | 01/01/2011 | - | |
Amministratore Delegato | 01/01/2011 | - |
Storia della carriera di Joseph H. Gardner
Precedenti posizioni note di Joseph H. Gardner
Società | Posizione | Inizio | Fine |
---|---|---|---|
AERPIO PHARMACEUTICALS | Direttore/Membro del Consiglio | 16/11/2007 | 26/08/2021 |
Amministratore Delegato | 15/10/2019 | 26/08/2021 | |
Fondatore | 16/11/2007 | 26/08/2021 | |
Contatto Relazioni con gli Investitori | 16/11/2007 | 26/08/2021 | |
Public Communications Contact | 16/11/2007 | 26/08/2021 | |
Presidente | 01/12/2011 | 26/08/2021 | |
AKEBIA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 27/02/2007 | 15/09/2013 |
Amministratore Delegato | 27/02/2007 | 15/09/2013 | |
Fondatore | 27/02/2007 | 15/09/2013 | |
Presidente | 27/02/2007 | 15/09/2013 | |
Procter & Gamble Pharmaceuticals, Inc.
Procter & Gamble Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Procter & Gamble Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its products include Actonel, Asacol, Enablex, Didronel, Macrobid, Macrodantin, Entex, and Ziac. The firm manufactures and markets a variety of over-the-counter and oral care products such as Crest, Oral-B, Prilosec OTC, Vicks, Metamucil, Pepto-Bismol, ThermaCare, and other related products. The company was founded in 1970 and is headquartered in Cincinnati, OH. | Corporate Officer/Principal | - | - |
JDRF International
JDRF International Miscellaneous Commercial ServicesCommercial Services JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY. | Direttore/Membro del Consiglio | - | - |
Formazione di Joseph H. Gardner
Tulane University (Louisiana) | Undergraduate Degree |
Utah State University | Graduate Degree |
University of Wisconsin | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 9 |
Posizioni
Director/Board Member | 4 |
Chief Executive Officer | 3 |
Founder | 3 |
Settori
Health Technology | 5 |
Consumer Services | 4 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
AKEBIA THERAPEUTICS, INC. | Health Technology |
Aziende private | 4 |
---|---|
JDRF International
JDRF International Miscellaneous Commercial ServicesCommercial Services JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY. | Commercial Services |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Health Technology |
Procter & Gamble Pharmaceuticals, Inc.
Procter & Gamble Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Procter & Gamble Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its products include Actonel, Asacol, Enablex, Didronel, Macrobid, Macrodantin, Entex, and Ziac. The firm manufactures and markets a variety of over-the-counter and oral care products such as Crest, Oral-B, Prilosec OTC, Vicks, Metamucil, Pepto-Bismol, ThermaCare, and other related products. The company was founded in 1970 and is headquartered in Cincinnati, OH. | Health Technology |
Aerpio Pharmaceuticals, Inc.
Aerpio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH. | Health Technology |
- Borsa valori
- Insiders
- Joseph H. Gardner
- Esperienza